Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
76,851,274
-
Total 13F shares
-
17,450,658
-
Share change
-
-577,730
-
Total reported value
-
$110,112,206
-
Price per share
-
$6.31
-
Number of holders
-
56
-
Value change
-
-$24,376,594
-
Number of buys
-
33
-
Number of sells
-
19
Institutional Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q4 2018
As of 31 Dec 2018,
Xenon Pharmaceuticals Inc. - Common Stock (XENE) was held by
56 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
17,450,658 shares.
The largest 10 holders included
venBio Select Advisor LLC, BVF INC/IL, Vivo Capital, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Capital World Investors, Aquilo Capital Management, LLC, Capital International Investors, CITADEL ADVISORS LLC, Point72 Asset Management, L.P., and ORBIMED ADVISORS LLC.
This page lists
56
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.